Medindia

X

Biocon to Launch Anti-arthritis Drug

by Medindia Content Team on  November 27, 2006 at 8:32 PM Drug News   - G J E 4
Biocon to Launch Anti-arthritis Drug
New Delhi: India's leading biotech firm Biocon Monday said it would launch in the next three-four years a new anti-arthritis drug which would have the potential to "be a multi-billion dollar opportunity for the company".
Advertisement

"The new molecule (T1H) which has completed phase II of clinical trials can prove to be a multi-billion opportunity for us," said Kiran Mazumdar Shaw, chairman and managing director of Biocon Ltd, on the sidelines of the 22nd Indian Economic Summit here.

Advertisement
"Phase III of the trails will start within the next 18 months and for that we are looking at global partners," she added.

The company is also looking at earning revenue of about $100 million from the recent cancer drug BIOMAb-EGFR, mainly from the Middle East market.

Biocon launched BIOMAb-EGFR last month for treating solid tumours of epithelial origin, such as head and neck cancers.

Source: IANS
SRM
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All